Craig M. Crews
Craig M. Crews
John C. Malone Professor of Molecular, Cellular, and Developmental Biology and Professor of Chemistry, Pharmacology, and Management, Yale University

CASE Member – Elected in 2015

Elected to the Academy in 2015

Craig Crews is a pioneering researcher who launched the pharmaceutical field of Targeted Protein Degradation (TPD). Described as an exceptionally creative scientist, with an eagerness to ask piercing, mechanism-based questions, and a commitment to evidence-based, first-rate, definitive science, he has had a profound translational impact in drug development.

Since 2001, Dr. Crews has developed a new technology, known as PROTACs, or Proteolysis Targeting Chimeras.  This innovative and potentially disruptive approach for inhibiting the function of disease-causing proteins is being commercialized in the biotechnology, New Haven-based, oncology-focused company Arvinas that he founded in 2013. The company focuses on drugs to treat cancer, neurodegeneration, and other diseases [now in clinical trials for breast and prostate cancer].

Crews earned a BA in Chemistry from the University of Virginia, completed a research fellowship at the University of Tübingen (Germany), and received his PhD in biochemistry from Harvard University. His awards and honors are numerous, including the 2013 CURE Entrepreneur of the Year Award, 2014 Ehrlich Award for Medicinal Chemistry, 2015 Yale Cancer Center Translational Research Prize, a NIH R35 Outstanding Investigator Award (2015), elected a CASE Member (2015), the American Association for Cancer Research Award for Chemistry in Cancer Research (2017), Khorana Prize from the Royal Society of Chemistry (2018), Pierre Fabre Award for Therapeutic Innovation (2018), the Pharmacia-ASPET Award for Experimental Therapeutics (2019), the Heinrich Wieland Prize (2020) and the Scheele Prize (2021).